Roxadustat Market Growth Outlook Reveals A CAGR Of 6.9% And A Market Value Of $9.56 Billion By 2030
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Roxadustat Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The roxadustat market experienced robust expansion over the recent period, with its value projected to rise from $6.86 billion in 2025 to $7.33 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.9%. Historically, this growth has been driven by several key factors, including the high prevalence of chronic kidney disease, reliance on erythropoiesis-stimulating agents, anemia management primarily within hospital settings, the scarcity of effective oral anemia treatments, and an increasing number of dialysis centers.
The roxadustat market is projected to experience robust expansion over the coming years, reaching a valuation of $9.56 billion by 2030, with a compound annual growth rate (CAGR) of 6.9%. This anticipated growth during the forecast period is driven by several key factors, including the increasing global prevalence of anemia, a growing preference for oral treatment options, an expanding population of patients with chronic kidney disease (CKD), a rise in outpatient anemia management practices, and enhanced availability of innovative anemia medications. Notable trends shaping this period include the increasing adoption of oral anemia therapies, the growing utilization of HIF-PHI drugs, a heightened focus on anemia associated with CKD, a gradual transition away from injectable erythropoiesis-stimulating agents (ESAs), and the broadening of access to anemia treatments.
Download A Free Sample Report For Comprehensive Market Insights:
Roxadustat Market Demand Drivers Creating New Revenue Opportunities
The growing prevalence of chronic kidney disease (CKD) is anticipated to drive the expansion of the Roxadustat market in the coming years. Chronic kidney disease (CKD) is a progressive condition in which the kidneys steadily lose their ability to function correctly, potentially culminating in kidney failure if not addressed. Worldwide, the incidence of CKD is increasing due to aging populations, higher rates of diabetes and hypertension, and unhealthy lifestyle choices. Roxadustat aids in managing CKD by promoting erythropoietin production, which boosts red blood cell generation and alleviates the anemia frequently linked to the disease, thus enhancing kidney performance and patient quality of life. For example, in June 2023, Kidney Research UK, a UK-based charity, reported that by 2033, the number of individuals with CKD stages 3–5 is projected to reach 3.9 million. Consequently, the rising number of people affected by chronic kidney disease (CKD) is fueling growth in the Roxadustat market.
Roxadustat Market Segment Breakdown: Which Categories Generate The Most Revenue?
The roxadustat market covered in this report is segmented –
1) By Type: 20mg, 50mg
2) By Product Formulation: Oral Tablets
3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers
4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions
Roxadustat Market Trends Driving Strategic Industry Expansion
Key players in the roxadustat market are increasingly prioritizing the generation of real-world evidence—such as observational registry studies—to confirm the lasting value, safety, and usage trends of their HIF PH inhibitor therapy. This type of evidence involves clinical information gathered outside controlled trials, in everyday healthcare environments, to capture genuine patient outcomes. By sponsoring extensive real-world investigations, the roxadustat market responds to growing demands from healthcare payers and regulators for such evaluations. A notable example occurred in May 2024, when Astellas Pharma, headquartered in the UK, initiated the WINE study through the WiNe Registry in Germany. This non-interventional cohort study tracks clinical results, dosing patterns, and hemoglobin levels in patients using EVRENZO (roxadustat). Findings from this registry highlight roxadustat’s efficacy in real-world chronic kidney disease populations and assist in securing long-term reimbursement. Consequently, the creation of real-world evidence is propelling expansion within the roxadustat market.
Roxadustat Market Key Players And Strategic Industry Positioning
Major companies operating in the roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy’s Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd.
Access The Complete Roxadustat Market Report:
Roxadustat Market Largest Region By Revenue And Market Share
North America was the largest region in the Roxadustat market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.